KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 15 years of Total Non-Current Liabilities data on record, last reported at $7.3 billion in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 8.59% year-over-year to $7.3 billion; the TTM value through Sep 2025 reached $7.3 billion, down 8.59%, while the annual FY2024 figure was $7.8 billion, 3.96% up from the prior year.
  • Total Non-Current Liabilities reached $7.3 billion in Q3 2025 per JAZZ's latest filing, up from $7.1 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $8.9 billion in Q2 2021 and bottomed at -$3.9 billion in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $5.7 billion, with a median of $7.5 billion recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 230.85% in 2022, then skyrocketed 328.46% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $8.2 billion in 2021, then dropped by 7.2% to $7.6 billion in 2022, then dropped by 0.95% to $7.5 billion in 2023, then increased by 3.96% to $7.8 billion in 2024, then fell by 6.94% to $7.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $7.3 billion in Q3 2025, $7.1 billion in Q2 2025, and $7.3 billion in Q1 2025.